Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$370M+23.0% YoY

Gross Profit

$252M68.1% margin

Operating Income

$100M27.1% margin

Net Income

$131M35.4% margin

EPS (Diluted)

$1.87

QoQ Revenue Growth

+4.5%

Cash Flow

Operating Cash Flow

$127M

Free Cash Flow

$119M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$886M

Stockholders' Equity

$946M

Cash & Equivalents

$718M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$370M	$301M	+23.0%
Gross Profit	$252M	$77M	+226.7%
Operating Income	$100M	-$9M	+1174.3%
Net Income	$131M	-$3M	+4769.3%

Revenue Segments

Product

$369M33%

Radiopharmaceutical Oncology

$259M23%

PYLARIFY

$259M23%

Total Precision Diagnostics

$104M9%

DEFINITY

$77M7%

Techne Lite

$22M2%

Strategic Partnerships And Other

$7M1%

Other Precision Diagnostics

$6M1%

License and Royalty Revenues

$662,0000%

Other Radiopharmaceutical Oncology

$384,0000%